This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lu, Y. Articles by Franzusoff, A. Search for Related Content PubMed PubMed Citation Articles by Lu, Y. Articles by Franzusoff, A.

Mutation-Selective Tumor Remission with Ras-Targeted, Whole Yeast-Based Immunotherapy

¹ GlobeImmune, Inc., Aurora, Colorado; and ² University of Colorado Cancer Center, ³ School of Pharmacy, and ⁴ Department of Immunology and Medicine, University of Colorado Health Sciences Center, Denver, Colorado

Activating mutations in Ras oncoproteins represent attractive targets for cancer immunotherapy, but few vectors capable of generating immune responses required for tumor killing without vector neutralization have been described. Whole recombinant yeast heterologously expressing mammalian mutant Ras proteins were used to immunize mice in a carcinogen-induced lung tumor model. Therapeutic immunization with the whole recombinant yeast caused complete regression of established Ras mutation-bearing lung tumors in a dose-dependent, antigen-specific manner. In combination with the genomic sequencing of tumors in patients, the yeast-based immunotherapeutic approach could be applied to treat Ras mutation-bearing human cancers.

This article has been cited by other articles:

				E. K. Wansley, M. Chakraborty, K. W. Hance, M. B. Bernstein, A. L. Boehm, Z. Guo, D. Quick, A. Franzusoff, J. W. Greiner, J. Schlom, et al. Vaccination with a Recombinant Saccharomyces cerevisiae Expressing a Tumor Antigen Breaks Immune Tolerance and Elicits Therapeutic Antitumor Responses Clin. Cancer Res., July 1, 2008; 14(13): 4316 - 4325. [Abstract] [Full Text] [PDF]

				S. W. Howland and K. D. Wittrup Antigen Release Kinetics in the Phagosome Are Critical to Cross-Presentation Efficiency J. Immunol., February 1, 2008; 180(3): 1576 - 1583. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr., E. B. Haura, and J. V. Heymach Emerging Therapies for Non-small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): e5 - e14. [Abstract] [Full Text] [PDF]

				A. Zundelevich, G. Elad-Sfadia, R. Haklai, and Y. Kloog Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid) Mol. Cancer Ther., June 1, 2007; 6(6): 1765 - 1773. [Abstract] [Full Text] [PDF]

				E. F. Redente, D. J. Orlicky, R. J. Bouchard, and A. M. Malkinson Tumor Signaling to the Bone Marrow Changes the Phenotype of Monocytes and Pulmonary Macrophages during Urethane-Induced Primary Lung Tumorigenesis in A/J Mice Am. J. Pathol., February 1, 2007; 170(2): 693 - 708. [Abstract] [Full Text] [PDF]